IT1274350B - Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 - Google Patents

Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Info

Publication number
IT1274350B
IT1274350B ITRM940794A ITRM940794A IT1274350B IT 1274350 B IT1274350 B IT 1274350B IT RM940794 A ITRM940794 A IT RM940794A IT RM940794 A ITRM940794 A IT RM940794A IT 1274350 B IT1274350 B IT 1274350B
Authority
IT
Italy
Prior art keywords
antagonists
consist
interface
soluble forms
interleuchina
Prior art date
Application number
ITRM940794A
Other languages
English (en)
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Priority to ITRM940794A priority Critical patent/IT1274350B/it
Publication of ITRM940794A0 publication Critical patent/ITRM940794A0/it
Priority to EP95940401A priority patent/EP0742794A1/en
Priority to PCT/IT1995/000208 priority patent/WO1996017869A2/en
Priority to CA002177837A priority patent/CA2177837A1/en
Priority to AU41866/96A priority patent/AU4186696A/en
Priority to CN95191457A priority patent/CN1139933A/zh
Priority to JP8517466A priority patent/JPH09503232A/ja
Publication of ITRM940794A1 publication Critical patent/ITRM940794A1/it
Application granted granted Critical
Publication of IT1274350B publication Critical patent/IT1274350B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Si tratta di antagonisti di interleuchina-6, caratterizzati dal fatto di consistere di forme solubili del recettore ? di IL-6 umana (shIL-6R?) contenenti una o più mutazioni nell'interfaccia che si lega a gp 130. In una variante preferita, le mutazioni sono presenti in una posizione scelta dal gruppo comprendente Ala 228, Asn 230, His 280 e Asp 281. Questi antagonisti possono essere usati come agenti capaci di prevenire e curare malattie causate da una anormale attività di IL-6.La figura 4 mostra l'attività antagonistica del mutante Ala228Asp/Asn230Asp/His280Ser/Asp281Val in confronto alle proprietà agonistiche di shIL-6R? di tipo selvatico. Questo antagonista può essere usato per la preparazione di farmaci per la prevenzione, il controllo e la cura delle malattie dovute ad una anormale bioattività di IL-6.
ITRM940794A 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 IT1274350B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
EP95940401A EP0742794A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
PCT/IT1995/000208 WO1996017869A2 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
CA002177837A CA2177837A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
CN95191457A CN1139933A (zh) 1994-12-06 1995-12-05 由在GP130结合介面突变的白细胞介素-6(IL-6)受体α的可溶形式组成的IL-6拮抗剂
JP8517466A JPH09503232A (ja) 1994-12-06 1995-12-05 ＧＰ１３０結合界面で突然変異したインターロイキン−６（ＩＬ−６）受容体αの可溶性型であるＩＬ−６アンタゴニスト

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Publications (3)

Publication Number Publication Date
ITRM940794A0 ITRM940794A0 (it) 1994-12-06
ITRM940794A1 ITRM940794A1 (it) 1996-06-06
IT1274350B true IT1274350B (it) 1997-07-17

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Country Status (7)

Country Link
EP (1) EP0742794A1 (it)
JP (1) JPH09503232A (it)
CN (1) CN1139933A (it)
AU (1) AU4186696A (it)
CA (1) CA2177837A1 (it)
IT (1) IT1274350B (it)
WO (1) WO1996017869A2 (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
ES2319340T3 (es) * 1995-09-28 2009-05-06 Yeda Research And Development Co., Ltd. Peptidos sinteticos que inhiben la actividad de il-6.
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
EP1206275B1 (en) * 1998-11-05 2007-09-05 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
WO2001016166A2 (en) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
CA2516945A1 (en) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
RU2554942C2 (ru) 2003-10-17 2015-07-10 Тугаи Сейяку Кабусики Кайся Терапевтический агент для мезотелиомы
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
CA3103975A1 (en) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN110133241B (zh) * 2019-05-21 2022-05-27 中国食品药品检定研究院 一种测定重组人可溶性gp130-Fc融合蛋白生物学活性的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3363463B2 (ja) * 1991-10-02 2003-01-08 忠三 岸本 Ｉｌ−６レセプター誘導体

Also Published As

Publication number Publication date
JPH09503232A (ja) 1997-03-31
CN1139933A (zh) 1997-01-08
ITRM940794A0 (it) 1994-12-06
ITRM940794A1 (it) 1996-06-06
WO1996017869A3 (en) 1996-08-29
CA2177837A1 (en) 1996-06-07
AU4186696A (en) 1996-06-26
WO1996017869A2 (en) 1996-06-13
EP0742794A1 (en) 1996-11-20

Similar Documents

Publication Publication Date Title
WO1996017869A3 (en) Interleukin-6 (il-6) antagonists
Kris et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
HUP0101694A1 (hu) Gyulladásos bélbetegségek kezelésére vagy megelőzésére szolgáló, hatóanyagként IL-6 antagonistát tartalmazó készítmény
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
MY146986A (en) Methods for treating interleukin-6 related diseases
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO1999017755A3 (en) Medicaments
DOP2002000429A (es) Imidazotriazinas
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
JP2004537500A5 (it)
CA2439879A1 (en) C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
RU98101907A (ru) Терапевтические агенты и аутоимунные заболевания
HUP0401805A2 (hu) Pulmonális betegségek kezelésére szolgáló vegyületek
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
HUP0001526A2 (hu) Nukleozidok alkalmazása citokinekkel kapcsolatos megbetegedések kezelésére szolgáló gyógyszerkészítmények előállítására és gyógyszerkészítmények
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
CA2274063A1 (en) Substituted pyrimidine compounds and their use
GB9930077D0 (en) Medicaments
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction

Legal Events

Date Code Title Description
0001 Granted